These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9725548)

  • 1. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.
    Ebert U; Siepmann M; Oertel R; Wesnes KA; Kirch W
    J Clin Pharmacol; 1998 Aug; 38(8):720-6. PubMed ID: 9725548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD; Oertel R; Kirch W
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers.
    Ebert U; Grossmann M; Oertel R; Gramatté T; Kirch W
    J Clin Pharmacol; 2001 Jan; 41(1):51-60. PubMed ID: 11144994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs, memory, and metamemory: a dose-effect study with lorazepam and scopolamine.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):336-47. PubMed ID: 16366764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine.
    Fredrickson A; Snyder PJ; Cromer J; Thomas E; Lewis M; Maruff P
    Hum Psychopharmacol; 2008 Jul; 23(5):425-36. PubMed ID: 18421801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.
    Liem-Moolenaar M; de Boer P; Timmers M; Schoemaker RC; van Hasselt JG; Schmidt S; van Gerven JM
    Br J Clin Pharmacol; 2011 Jun; 71(6):886-98. PubMed ID: 21306419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.
    Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D
    Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine-antagonistic, anticholinergic, and GABAergic effects on declarative and procedural memory functions.
    Rammsayer TH; Rodewald S; Groh D
    Brain Res Cogn Brain Res; 2000 Jan; 9(1):61-71. PubMed ID: 10666558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.
    Alvarez-Jimenez R; Groeneveld GJ; van Gerven JM; Goulooze SC; Baakman AC; Hay JL; Stevens J
    Br J Clin Pharmacol; 2016 Oct; 82(4):1011-21. PubMed ID: 27273555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of scopolamine in serum and subcutaneous adipose tissue in healthy volunteers.
    Stetina PM; Madai B; Kulemann V; Kirch W; Joukhadar C
    Int J Clin Pharmacol Ther; 2005 Mar; 43(3):134-9. PubMed ID: 15792397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anticholinergic drugs and CNS relevance for therapy].
    Madersbacher H
    Krankenpfl J; 2005; 43(7-10):187-8. PubMed ID: 16515260
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.
    Duka T; Ott H; Rohloff A; Voet B
    Psychopharmacology (Berl); 1996 Feb; 123(4):361-73. PubMed ID: 8867876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2003 Feb; 11(1):56-72. PubMed ID: 12622344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
    Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of grapefruit juice on scopolamine pharmacokinetics and pharmacodynamics in healthy male and female subjects.
    Ebert U; Oertel R; Kirch W
    Int J Clin Pharmacol Ther; 2000 Nov; 38(11):523-31. PubMed ID: 11097144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans.
    Ellis JR; Ellis KA; Bartholomeusz CF; Harrison BJ; Wesnes KA; Erskine FF; Vitetta L; Nathan PJ
    Int J Neuropsychopharmacol; 2006 Apr; 9(2):175-89. PubMed ID: 15877932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of scopolamine on matching to sample paradigm and related tests in human subjects.
    Koller G; Satzger W; Adam M; Wagner M; Kathmann N; Soyka M; Engel R
    Neuropsychobiology; 2003; 48(2):87-94. PubMed ID: 14504417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing peripheral and central cholinergic system responses.
    Naranjo CA; Fourie J; Herrmann N; Lanctôt KL; Birt C; Yau KK
    J Psychiatry Neurosci; 2000 Sep; 25(4):325-36. PubMed ID: 11022397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR; Gonen A; Nachum Z; Doweck I; Spitzer O; Shupak A
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.